We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease

By LabMedica International staff writers
Posted on 25 Apr 2025

Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. More...

These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune diseases. Now, new research has revealed that a specific subset of neutrophils can predict disease relapse early, potentially paving the way for more tailored treatment approaches.

A study published in Nature Communications and led by a multi-institutional research team from The University of Osaka (Osaka, Japan) explored the dominant cell types in the blood of patients at the early stages of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This disease, caused by inflammation in the blood vessels, can lead to organ dysfunction. The research team enrolled six patients and seven healthy controls for comparison, collecting around 180,000 white blood cells. These cells were subjected to single-cell analysis to examine their genetic characteristics and surface proteins. The analysis of the transcriptome and proteome revealed a significantly higher proportion of two specific neutrophil subpopulations in the patients compared to healthy individuals. Notably, the researchers found an increase in a highly activatable subset of neutrophils in the patients. These cells were found to be responsive to interferon-gamma (IFN-g), a key protein involved in inflammation.

Among the patients, those showing the highest expression of IFN-g response genes were found to have persistent vasculitis symptoms even after treatment, suggesting that this particular neutrophil subpopulation plays a role in the persistent nature of vasculitis. To further investigate, the team analyzed the levels of IFN-g in stored serum samples from 37 patients, some of whom were newly diagnosed and others who had undergone treatment. The results were striking. Of the 24 new-onset patients assessed, the six with the highest serum IFN-g concentrations all experienced relapses, suggesting that measuring IFN-g levels could serve as an early indicator of disease relapse. This research offers a deeper understanding of the immune mechanisms underlying ANCA-associated vasculitis and suggests potential new strategies for disease monitoring and treatment. By identifying specific neutrophil populations involved in disease progression, these findings could lead to more personalized therapies, ultimately improving outcomes for patients suffering from this rare but serious condition.

Related Links:
University of Osaka 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.